Arcus Biosciences - Funding, Financials, Valuation, Investors - Cointime

Piyasa yapıcıların “kara kutusu”nu açıklığa kavuşturmak için on soru ve on cevap: Girişim sermayedarları piyasa yapıcılığa neden katılırlar? Proje sahipleri gerçekten arkadan bıçaklanmaya karşı savunmasız mı?

Bitcoin $84,123.39 +1.86%
Ethereum $1,930.70 +2.36%
BNB $630.33 +4.86%
Optimism $0.89 +6.74%
Arbitrum $0.37 +6.19%
Solana $128.36 +1.76%
Polygon $0.21 +2.49%
Cosmos $4.64 +0.14%
Avalanche $18.85 +2.94%

Bitcoin $84,123.39 +1.86%
Ethereum $1,930.70 +2.36%
BNB $630.33 +4.86%
Optimism $0.89 +6.74%
Arbitrum $0.37 +6.19%
Solana $128.36 +1.76%
Polygon $0.21 +2.49%
Cosmos $4.64 +0.14%
Avalanche $18.85 +2.94%

Arcus Biosciences

company

Investors

Number of Lead Investors

Number of Investors

3

18

Arcus Biosciences is funded by 18 investors. Gilead Sciences and GV are the most recent investors.

Investor Name	Lead Investor	Funding Round
Gilead Sciences	Yes	Post-IPO Equity
GV	Yes	Series C
Aisling Capital	-	Series C
Biotechnology Value Fund	-	Series C
Celgene	-	Series C
Decheng Capital	-	Series C
Droia Ventures	-	Series C
EcoR1 Capital	-	Series C
Foresite Capital	-	Series C
Hillhouse Capital Group	-	Series C
Invus	-	Series C
Leerink Partners	-	Series C
Taiho Ventures	-	Series C
The Column Group	-	Series C
Wellington Management	-	Series C
Novartis	-	Series B
RTA Capital	-	Series B
Stanford University	-	Series B